

# The Significance and Management of Thrombocytopeni

Current Rheumatology Reports

17, 14

DOI: [10.1007/s11926-014-0494-8](https://doi.org/10.1007/s11926-014-0494-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current status and future prospects for the treatment of antiphospholipid syndrome. Expert Review of Clinical Immunology, 2016, 12, 927-935.	3.0	8
2	Association of anticardiolipin, antiphosphatidylserine, anti- $\beta$ 2 glycoprotein I, and antiphosphatidylcholine autoantibodies with canine immune thrombocytopenia. BMC Veterinary Research, 2016, 12, 106.	1.9	2
3	The role of platelets in antiphospholipid syndrome. Platelets, 2017, 28, 762-766.	2.3	40
4	Clinical Reasoning: A young woman with progressive headache and pancytopenia. Neurology, 2017, 88, e132-e136.	1.1	0
5	Anti-phospholipid syndrome: Current opinion on mechanisms involved, laboratory characterization and diagnostic aspects. Transfusion and Apheresis Science, 2017, 56, 612-625.	1.0	10
7	Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study. Journal of Thrombosis and Haemostasis, 2017, 15, 1782-1787.	3.8	46
8	Antiphospholipid Syndrome: Multiple Manifestations in a Single Patientâ€”A High Suspicion Is Still Needed. Case Reports in Medicine, 2017, 2017, 1-4.	0.7	3
9	Thrombocytopenia in high-risk patients with antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2018, 16, 529-532.	3.8	39
10	Chronic Thromboembolic Pulmonary Hypertension and Antiphospholipid Syndrome with Immune Thrombocytopenia: A Case Report. American Journal of Case Reports, 2018, 19, 1245-1248.	0.8	2
11	Antiphospholipid Syndrome and Thrombocytopenia. , 2018, , .		2
12	Suspected systemic rheumatic diseases in patients presenting with cytopenias. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101425.	3.3	5
13	Autoimmune haemolytic anaemia and thrombocytopenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: clinical associations and effect on disease damage and survival. Lupus, 2019, 28, 1480-1487.	1.6	8
14	Thrombotic complications in adult patients with severe single coagulation factor or platelet defects â€” an overview. Expert Review of Hematology, 2019, 12, 119-128.	2.2	2
15	Challenges in Treating Extensive Deep Vein Thrombosis with Severe Thrombocytopenia in Patients with Antiphospholipid Syndromeâ€”A Follow-up of 2 Years. International Journal of Angiology, 2024, 33, 066-069.	0.6	0
16	Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome. Current Opinion in Rheumatology, 2019, 31, 231-240.	4.3	22
17	Multifocal avascular necrosis in a patient with refractory immune thrombocytopenia and antiphospholipid antibodies; case report and review of literature. Platelets, 2019, 30, 664-671.	2.3	3
18	Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome. Seminars in Arthritis and Rheumatism, 2019, 48, 741-744.	3.4	12
19	Potential therapeutics for antiphospholipid antibody associated thrombocytopenia: A systematic review and meta-analysis. Modern Rheumatology, 2020, 30, 116-124.	1.8	3

#	ARTICLE	IF	CITATIONS
20	How Can I Manage Thrombocytopenia in Hemodialysis Patient? A Review. Therapeutic Apheresis and Dialysis, 2020, 24, 352-360.	0.9	5
21	Management of Non-criteria Manifestations in Antiphospholipid Syndrome. Current Rheumatology Reports, 2020, 22, 51.	4.7	22
22	High risk of systemic lupus erythematosus development in patients with ITP: antiphospholipid syndrome is also a concern. Annals of the Rheumatic Diseases, 2022, 81, e110-e110.	0.9	1
23	Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management. Haematologica, 2020, 105, 562-572.	3.5	81
24	Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study. Annals of the Rheumatic Diseases, 2020, 79, 793-799.	0.9	53
25	Antiphospholipid syndrome presenting as treatment resistant bipolar disorder and thrombocytopenia in a young male. Journal of Neuroimmunology, 2020, 343, 577238.	2.3	1
26	Primary Antiphospholipid Antibody Syndrome"Associated Severe Thrombocytopenia and Thrombosis Treated Successfully With "Quadruple Therapy". Journal of Clinical Rheumatology, 2021, 27, e208-e210.	0.9	0
27	Non-Criteria Manifestations of Juvenile Antiphospholipid Syndrome. Journal of Clinical Medicine, 2021, 10, 1240.	2.4	8
28	Risk of Systemic Lupus Erythematosus in Patients With Anti-phospholipid Syndrome: A Population-Based Study. Frontiers in Medicine, 2021, 8, 654791.	2.6	7
29	Bleeding in Patients with Antiphospholipid Antibodies. , 0, , .		0
30	CIRCULATING LEVEL OF INTERLEUKIN 6 IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME. Al Azhar Medical Journal = Majallat Al-Tibb Al-Azhar, 2021, 50, 2271-2280.	0.1	0
31	Osteonecrosis in Primary Antiphospholipid Syndrome is Associated with Previous Glucocorticoid Use and Thrombocytopenia. Rheumatology and Therapy, 2021, 8, 1255-1261.	2.3	1
32	Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?. Biomedicines, 2021, 9, 1170.	3.2	14
33	The high prevalence of abnormal MRI findings in non-neuropsychiatric patients with persistently positive antiphospholipid antibodies. Rheumatology, 2021, , .	1.9	2
34	Treatment of Non-criteria Manifestations in Antiphospholipid Syndrome. , 2017, , 247-266.		4
35	Diagnosis in General. , 2017, , 87-95.		1
36	Chronic thromboembolic pulmonary hypertension in patients with antiphospholipid syndrome: Risk factors and management. Journal of Heart and Lung Transplantation, 2022, 41, 208-216.	0.6	5
37	Thrombosis with Thrombocytopenia - A Vascular Paradox. Journal of Evidence Based Medicine and Healthcare, 2020, 7, 3110-3116.	0.0	0

#	ARTICLE	IF	CITATIONS
39	Platelet Activation Mechanisms and Consequences of Immune Thrombocytopenia. <i>Cells</i> , 2021, 10, 3386.	4.1	35
40	Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2020, 7, 180-183.	0.6	2
41	Thrombocytopenia in a cohort of primary and secondary antiphospholipid syndrome patients: Relation to clinical, laboratory manifestations and damage index. <i>Archives of Rheumatology</i> , 2022, 37, 252-260.	0.9	2
42	Refractory antiphospholipid antibody syndromeâ€“induced thrombocytopaenia successfully treated with belimumab. <i>Lupus</i> , 2022, 31, 624-627.	1.6	3
43	Pulmonary Endarterectomy in Patients with Antiphospholipid Syndrome-Associated Chronic Thromboembolic Pulmonary Hypertension. , 2022, 26, 394-400.		3
44	Postural tachycardia syndrome (POTS) and antiphospholipid syndrome (APS): What do we know so far?. <i>Revue Neurologique</i> , 2022, 178, 306-314.	1.5	2
46	Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications. <i>Rheumatology</i> , 2022, 62, 256-263.	1.9	11
47	Antiphospholipid Syndrome-Related Pulmonary Embolism: Clinical Characteristics and Early Recognition. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	4
48	Pathogenetic significance of antiphospholipid antibodies in the development of placenta-associated complications in pregnant women with thrombocytopenia. <i>Journal of Obstetrics and Women's Diseases</i> , 2022, 71, 13-20.	0.2	0
49	A novel aGAPSS-based nomogram for the prediction of ischemic stroke in patients with antiphospholipid syndrome. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
50	Thrombocytopenia in the first trimester predicts adverse pregnancy outcomes in obstetric antiphospholipid syndrome. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
51	Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis. <i>Blood Reviews</i> , 2023, 58, 101015.	5.7	5
52	Clinical phenotype, treatment strategy and pregnancy outcome of nonâ€“criteria obstetric antiphospholipid syndrome. <i>American Journal of Reproductive Immunology</i> , 0, , .	1.2	1
53	Wolf Bite. , 2023, , 535-543.		0
54	Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
55	Efficacy of telitacicept in patients with lupusâ€“and antiphospholipid syndromeâ€“associated refractory thrombocytopenia. <i>Rheumatology &amp; Autoimmunity</i> , 2023, 3, 120-124.	0.8	0
56	Primary and secondary immune thrombocytopenia (ITP): Time for a rethink. <i>Blood Reviews</i> , 2023, 61, 101112.	5.7	3
57	Oligosymptomatic infection by SARS-Cov-2 in catastrophic antiphospholipid syndrome, a singular coincidence: a case report in an Ecuadorian hospital. <i>Hematology, Transfusion and Cell Therapy</i> , 2023, , .	0.2	0

#	ARTICLE	IF	CITATIONS
59	Serum Calprotectin as a Potential Predictor of Microvascular Manifestations in Patients with Antiphospholipid Syndrome. <i>Rheumatology and Therapy</i> , 2023, 10, 1769-1783.	2.3	0
61	Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study. <i>Arthritis Research and Therapy</i> , 2024, 26, .	3.5	0